Teaching Hospital, Lusaka, Zambia
African Medical Research Council, Durban, South Africa
South Africa MRC website and University of Natal - website.
|Reproductive Health and HIV Research Unit, University of Witswatersrand, Johannesburg, South Africa
Reproductive Health and HIV Research Unit website.
NIMR and LSHTM, Mwanza, Tanzania
AMREF website and LSHTM website.
College at St Mary's Hospital
Imperial College's website and St Mary's website.
|MRC/Uganda Virus Research Institute, Entebbe, Uganda
Africa Centre for Health and Population Studies,
Africa Centre website
All the six clinical trial sites are currently recruiting into the Phase III trial to test the effectiveness of of PRO2000/5 1.
The sites all completed preparatory feasibility and pilot studies prior to commencing the Phase III. During feasibility women were recruited (or couples) into HIV testing and counselling schemes, either using existing health systems, if appropriate, or providing new services. The feasibility stage served several purposes; it provided baseline prevalence and incidence data on HIV, other STIs and pregnancies; it built sufficient clinical and laboratory research capacity at the sites; and it showed whether it was possible to recruit and retain sufficient women for the trial from these populations.
Recruitment Target: 9673
Accrual at end of recruitment as of 15 August 2008: 9404
1 PRO2000/5 (Indevus) is a sulphonated polymer which appears to block adhesion of the HIV virus to vaginal epithelia. Phase I/II safety studies conducted in the UK, Belgium, USA and South Africa have been successfully completed.
|The Zambian MDP team, based
|The MDP clinic at Mazabuka
|Reproductive Health and HIV
Research Unit's clinic
|The entrance to Chris Hani Baragwanath
Hospital, Soweto site of Reproductive Health and HIV Research Unit